profit from every $100 of sales.
$0$100
MapLight Therapeutics
$7.44+2.20% today
-47.9% in 1 year
1-year low $6.221-year high $39.80
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
MapLight Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| MapLight Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.0× · Fair price | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads MapLight Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2025 |
|---|---|
| 0 | |
| – | |
| -169 | |
| -169 | |
| -161 | |
| -18.56 | |
| – | |
| – | |
| – |
Balance sheet
| In millions of USD | 2025 |
|---|---|
| Total assets | 480 |
| Cash | 47 |
| Total debt | 6 |
| Total liabilities | 21 |
| 458 | |
| 9 | |
| -28.8% | |
| -35.2% |
Cash flow
| In millions of USD | 2025 |
|---|---|
| -138 | |
| 0 | |
| -139 | |
| Dividends paid | – |
| – | |
| 36 |
Valuation
- –
- –
- –
- 2.6×
- –
- –
- 0.1×
- -33.5%
- -39.0%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -36.4%
- -70.3%
- -76.0%
- -33.6%
- -36.5%
- –
Growth
- –
- –
- −74.2%
- –
- +2.0%
Financial health
- 0.2×
- 0.01
- 1.2%
- –
- 20.01
- 20.01
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 14%of 953
Bottom 21%of 877
Bottom 2%of 988
What analysts expect
- Average price target
- $33.80
- Range
- $28.00 – $45.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -1.34 | -0.96 | −39.3% |
| Dec 4, 2025 | -37.18 | -1.72 | −2,061.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
33No pass
Benjamin Graham
45No pass
Philip Fisher
36No pass
Peter Lynch
60Pass
Joel Greenblatt
40No pass
Charlie Munger
30No pass
Terry Smith
28No pass
Questions about MapLight Therapeutics
Is MapLight Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the MapLight Therapeutics AI analysis
What does MapLight Therapeutics do?
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. It is in Biotechnology.
Does MapLight Therapeutics pay a dividend?
No. MapLight Therapeutics does not pay a dividend at the moment.
Is MapLight Therapeutics stock halal?
Questionable. MapLight Therapeutics sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has MapLight Therapeutics stock done over the past year?
Down 47.9% over the past twelve months, to $7.44. It traded between $6.22 and $39.80 and is 81.3% below its high.
Who are MapLight Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with MapLight Therapeutics's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.